Announcement on Voluntary Disclosure of the Acceptance of New Drug Application for the ALK inhibitor Conteltinib (CT-707)

About this update from Shouyao Holdings Beijing Co. Ltd. Class A

Announcement on Voluntary Disclosure of the Acceptance of New Drug Application for the ALK inhibitor Conteltinib (CT-707) The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Shouyao Holdings Beijing Co. Ltd. Class A